[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolically-healthy-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolically-healthy-obesity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100635941","gut-immune-and-vascular-health-in-metabolically-healthy-obesity-100635941",false,"NCT07559227","Gut, Immune, and Vascular Health in Metabolically Healthy Obesity","Impaired Gut-Vascular Axis as a Unique Driver of Cardiovascular Disease in Metabolically Healthy Obesity","Inclusion Criteria:\n\n* 18-55 years old.\n* BMI is 18.5-24.9 kg\u002Fm2 or \\>30kg\u002Fm2 (part 1). BMI \\> 30 kg\u002Fm2 (part 2)\n* Not pregnant or expecting to become pregnant (females only).\n* Not postmenopausal (females only).\n* Have 0-1 risk factors based on blood pressure, blood sugar, triglycerides, and HDL-cholesterol (\"good cholesterol\").\n* Have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Have not been diagnosed with a chronic inflammatory or gastrointestinal condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs three days prior to the study visit.\n* Have not taken antibiotics or probiotics in the last month.\n* Do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin), or anti-hypertensive drugs.\n* Do not use weight-loss drugs (e.g., Ozempic, Wegovy).\n* Have not had any surgery that alters the stomach\u002Fgastrointestinal tract (e.g., gastric sleeve, gastric bypass).\n* Do not use tobacco products or any illicit drugs.\n* Do not have a pacemaker.\n* Do not have dietary restrictions prohibiting consumption of the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* Able to stay in the supine position in the dark for at least 10 minutes (related to vascular measurements)\n\nExclusion Criteria:\n\n* Not 18-55 years old.\n* BMI is not 18.5-24.9 kg\u002Fm2 or \\>30kg\u002Fm2 (part 1). BMI is not \\> 30 kg\u002Fm2 (part 2)\n* Pregnant or expecting to become pregnant (females only).\n* Postmenopausal (females only).\n* Do not have 0-1 risk factors based on blood pressure, blood sugar, triglycerides, and HDL-cholesterol (\"good cholesterol\").\n* Have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Have been diagnosed with a chronic inflammatory or gastrointestinal condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs three days prior to the study visit.\n* Have taken antibiotics or probiotics in the last month.\n* Use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin), or anti-hypertensive drugs.\n* Use weight-loss drugs (e.g., Ozempic, Wegovy).\n* Have had any surgery that alters the stomach\u002Fgastrointestinal tract (e.g., gastric sleeve, gastric bypass).\n* Use tobacco products or any illicit drugs.\n* Have a pacemaker.\n* Have dietary restrictions prohibiting consumption of the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* Not able to stay in the supine position in the dark for at least 10 minutes (related to vascular measurements)",true,"ALL","18 Years","55 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","The investigators seek to better understand how a single high-fat meal impacts gut, immune, and vascular outcomes in individuals with \"metabolically healthy obesity\" (obesity and largely normal cardiometabolic profile) and \"metabolically healthy normal-weight individuals.\" Second, the investigators seek to understand how a prebiotic fiber (inulin) impacts gut, immune, and vascular outcomes in individuals with \"metabolically healthy obesity.\"",[28],"Metabolically Healthy Obesity",[30,31,32,33],"Gut-vascular axis","Intestinal permeability","vascular function","obesity","RECRUITING","2026-04-23",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":38},"2026-03-01",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"Ball State University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100618336","breath-mass-spectrometry-in-metabolic-syndrome-and-metabolically-healthy-obesity-100618336","NCT07330297","Breath Mass Spectrometry in Metabolic Syndrome and Metabolically Healthy Obesity","The Capabilities of Exhaled Breath Mass Spectrometry in Identifying Metabolic Syndrome and Metabolically Healthy Obesity","Inclusion Criteria:\n\n* For Group 1 (Metabolic syndrome): Age \\>18 years, signed informed consent, diagnosis of Metabolic Syndrome (IDF 2006 criteria: waist circumference \\>94 cm (men)\u002F \\>80 cm (women) + ≥2 of: BP ≥130\u002F85 mmHg or antihypertensive therapy; TG ≥1.7 mmol\u002FL; HDL-C \\\u003C1.03 mmol\u002FL (men) \u002F \\\u003C1.29 mmol\u002FL (women); Fasting glucose ≥5.6 mmol\u002FL).\n* For Group 2 (Metabolically healthy obesity): Age \\>18 years, signed informed consent, waist circumference ≥94 cm (men) \u002F ≥80 cm (women), absence of other Metabolic Syndrome criteria (hypertension, dyslipidemia, impaired fasting glucose).\n* For Group 3 (Control): Age \\>18 years, signed informed consent, normal BMI, absence of signs of Metabolic Syndrome.\n\nNon-inclusion criteria for all groups:\n\n* Inability to provide informed consent;\n* History of myocardial infarction or stroke;\n* Chronic kidney disease stage 3B, 4, 5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2);\n* Acute or subacute cardiovascular disease;\n* Familial hypercholesterolemia;\n* Bronchopulmonary diseases;\n* Acute or chronic infectious diseases;\n* Type 1 or Type 2 diabetes mellitus;\n* Systemic connective tissue diseases;\n* Current or past history of oncological diseases;\n* Severe liver dysfunction, decompensated liver cirrhosis (Child-Pugh class C);\n* Pregnancy or lactation;\n* Severe mental illness (severe dementia, schizophrenia);\n* Comorbid conditions with life expectancy less than 1 year.\n\nExclusion Criteria:\n\n* Patient refusal to continue participation in the study;\n* Identification of any non-inclusion criteria after enrollment.",{"count":55,"type":22},300,"OBSERVATIONAL","This study aims to develop a non-invasive diagnostic method for metabolic syndrome (MetS) and metabolically healthy obesity (MHO) through analysis of exhaled air. Using proton-transfer-reaction mass spectrometry combined with machine learning algorithms, we will characterize volatile organic compound profiles in 300 participants across three groups: MetS patients, MHO patients, and healthy controls. The primary goal is to create and validate a classification model capable of accurately differentiating these metabolic states based on breath analysis.",[59,60,28],"Metabolic Syndrome","Obesity & Overweight",[62,63,64,65,66,67,68,69],"Breath Analysis","Volatile Organic Compounds","Proton-Transfer-Reaction Mass Spectrometry","Artificial Intelligence","Machine Learning","Metabolic syndrome","Obesity","Metabolically healthy obesity","2025-12-29",{"date":72,"type":38},"2026-01-09",{"date":74,"type":38},"2024-09-19",{"date":76,"type":22},"2026-12-30",{"name":78,"class":45},"I.M. Sechenov First Moscow State Medical University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100600279","impact-of-supplemental-fiber-on-gut-and-vascular-health-related-in-obesity-phenotypes-100600279","NCT07095426","Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes","Interplay Between Metabolic Risk Factors, Body Mass Index, and the Gut\u002FVascular Response to Supplemental Fiber","Inclusion Criteria:\n\n* Participants are 18-55 years old.\n* Participants BMI is ≥30 kg\u002Fm2 - this BMI requirement is due to our research aims.\n* Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.\n* Participants are not pregnant or expecting to become pregnant (females only). •Participants are not postmenopausal (females only).\n* Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis\u002Fdiverticulitis).\n* Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.\n* Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).\n* Participants do not use tobacco products or any illicit drugs.\n* Participants have not used antibiotics or probiotics in the last month.\n* Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies\u002Fintolerance).\n* Participants do not have a pacemaker.\n* Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).\n\nExclusion Criteria:\n\n* Participants are not 18-55 years old.\n* Participants BMI is not ≥30 kg\u002Fm2 - this BMI requirement is due to our research aims.\n* Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.\n* Participants are pregnant or expecting to become pregnant (females only).\n* Participants are postmenopausal (females only).\n* Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis\u002Fdiverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.\n* Participants take weight-loss medications (e.g., Ozempic, Wegovy).\n* Participants use tobacco products or any illicit drugs.\n* Participants have used antibiotics or probiotics in the last month.\n* Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies\u002Fintolerance).\n* Participants have a pacemaker.",{"count":87,"type":22},20,[25],"Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.",[59,91,28,92],"Healthy Participants","Metabolically Abnormal Obesity",[94,95,96,97],"fiber","vascular health","gut health","inflammation","2025-07-24",{"date":100,"type":38},"2025-07-31",{"date":102,"type":38},"2025-05-20",{"date":104,"type":22},"2027-05",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":17,"minAge":114,"maxAge":19,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":46},"100510997","small-extracellular-vesicles-and-insulin-action-100510997","NCT05933707","Small Extracellular Vesicles and Insulin Action","Effect of Small Extracellular Vesicles From Adipose Tissue on Insulin Action","SEV","Inclusion Criteria:\n\n* Metabolically healthy lean subjects must have a BMI ≥18.5 and ≤24.9 kg\u002Fm²; Subjects with obesity must have a BMI ≥30.0 and ≤50.0 kg\u002Fm²\n* Metabolically healthy lean and people with metabolically healthy obesity must have intrahepatic triglyceride (IHTG) content ≤5%; fasting plasma glucose concentration \\\u003C100 mg\u002Fdl, 2-hr oral glucose tolerance plasma glucose concentration \\\u003C140 mg\u002Fdl, hemoglobin A 1C (HbA1c) ≤5.6% and HOMA-IR \\\u003C2.5.\n* People with metabolically unhealthy obesity must have intrahepatic triglyceride (IHTG) content ≥5.6%; HOMA-IR ≥2.5, and HbA1c 5.7%-6.4%, or fasting plasma glucose concentration ≥100 mg\u002Fdl, or 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg\u002Fdl.\n\nExclusion Criteria:\n\n* History of diabetes, liver disease other than NAFLD or other serious diseases,\n* Consume excessive amounts of alcohol (\\>21 units\u002Fweek for men and \\>14 units\u002Fweek for women),\n* Take medications that could affect the study outcome measures, engage in regular exercise (\\>120 min\u002Fweek),\n* Are pregnant or lactating","25 Years",{"count":116,"type":22},72,[25],"The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.",[68,120,28,121],"Insulin Resistance","Obesity, Metabolically Benign",[68,123,124,125],"Weight Loss","Exosomes","Extracellular vesicles","2025-07-14",{"date":128,"type":38},"2025-07-17",{"date":130,"type":38},"2023-06-08",{"date":132,"type":22},"2029-09-01",{"name":134,"class":45},"Washington University School of Medicine"]